Keros Therapeutics’ KROS shares jumped 18.5% yesterday following an announcement that it is exploring strategic options, ...

Keros Therapeutics (KROS) stock surges 22% amid strategic review for sale and the adoption of a poison pill to protect ...

Local breweries might have an easier path to sell their products. Thursday, lawmakers overwhelmingly passed LB 113, allowing ...

Truist lowered the firm’s price target on Keros Therapeutics (KROS) to $25 from $43 and keeps a Buy rating on the shares as part of a broader ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Keros Therapeutics, Inc. (NASDAQ:KROS) suffered a major setback back in December 2024 when it announced that it had to halt its TROPOS phase 2 trial. This trial was evaluating the use of its drug ...

Truist Financial analyst Srikripa Devarakonda maintained a Buy rating on Keros Therapeutics (KROS – Research Report) today and set a price ...

Keros Therapeutics’ KROS shares jumped 18.5% yesterday following an announcement that it is exploring strategic options, including a potential sale of the business. To aid the decision process ...

Elevate your confidence by analyzing investor sentiment and stock portfolio shifts, then make your own decisions.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...